Food, drugs, devices › AuroMedics Pharma LLC

Drug recall: Amiodarone Hydrochloride Injection, USP, 150 mg per 3 mL (50 mg / mL), 3 mL Single Dose Vial, Rx only, Distributed by Au

FDA enforcement event 84240 · Class III · initiated 11 Nov 2019 · status Terminated · terminated 1 Apr 2021

DrugVoluntary: Firm initiated3 product recordsEast Windsor, NJ

FDA enforcement event 84240 is a drug recall by AuroMedics Pharma LLC of East Windsor, NJ, initiated 11 Nov 2019 and classified Class III, with 3 product records.

FDA defines Class III as a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences. 22% of the 362 drug enforcement events initiated in 2019 carry the same class.

Status: Terminated, terminated 1 Apr 2021. Initiation: voluntary: firm initiated. AuroMedics Pharma LLC has 23 enforcement events on this register, with a median of 1 product record per event.

Recall classification reflects the relative degree of health hazard. Text in quotation marks is FDA's. openFDA export dated 28 Sep 2026.

Recalling firm

AuroMedics Pharma LLC, East Windsor, NJ.

Reason for recall

"Crystallization: Presence of visible particulate matter."

Distribution

"Distributed Nationwide in the US"

Product records

Recall number	Product	Quantity	Class	Status	Report date
D-0520-2020	Amiodarone Hydrochloride Injection, USP, 150 mg per 3 mL (50 mg / mL), 3 mL Single Dose Vial, Rx only, Distributed by AuroMedics Pharma LLC E. Windsor, NJ. 08520, Made in India. NDC 55150-180-03	28,810 vials	Class III	Terminated	4 Dec 2019
D-0521-2020	Amiodarone Hydrochloride Injection, USP, 450 mg per 9 mL (50 mg / mL), 9 mL Single Dose Vial, Rx only, Distributed by AuroMedics Pharma LLC E. Windsor, NJ. 08520, Made in India. NDC 55150-181-09	29,830 vials	Class III	Terminated	4 Dec 2019
D-0522-2020	Amiodarone Hydrochloride Injection, USP, 900 mg per 18 mL (50 mg / mL), 18 mL Multiple Dose Vial, Rx only, Distributed by AuroMedics Pharma LLC E. Windsor, NJ. 08520, Made in India. NDC 55150-182-18	138,720 vials	Class III	Terminated	4 Dec 2019

Context

22%of 2019 drug events are Class III362 events that year

3product records in this eventfirm median: 1

23events on this register for the firm

Other enforcement events for AuroMedics Pharma LLC

Initiated	Product (first record)	Type	Class	Records
30 Sep 2022	Fondaparinux Sodium Injection, USP, 7.5 mg per 0.6 mL, Single Dose, Prefilled Syringe, Distributed by: AuroMedics Pharma	Drug	Class II	1
26 Sep 2022	Tranexamic Acid Injection, USP, 1000mg per 10 mL (100mg /mL), 10mL single-dose vial, Rx Only, Distributed by: AuroMedics	Drug	Class III	1
26 Sep 2022	Acyclovir Sodium Injection, 500mg/10mL (50mg/mL), 10 mL Single Dose Vial, Rx only, Distributed by: AuroMedics Pharma LLC	Drug	Class II	1
26 Jan 2022	Polymyxin B for Injection USP, 500,000 Units per Vial, 10 mL vials, packaged in 10 vials per carton, Sterile, Rx Only, D	Drug	Class I	1
30 Dec 2020	Acetaminophen Injection 1,000 mg per 100 mL (10 mg/mL), 100 mL Single Dose Vial, For Intravenous Use Only, Distributed b	Drug	Class II	1
7 Feb 2020	Amoxicillin and Clavulanate Potassium Tablets, USP, 875 mg/125 mg, 20-count bottles, Distributed by: Aurobindo Pharma US	Drug	Class II	1
7 Feb 2020	Glycopyrrolate Injection, USP 4 mg per 20 mL (0.2 mg/mL), 20 mL Multiple Dose Vial, Rx Only, For Intramuscular or Intrav	Drug	Class III	1
2 Dec 2019	Moxifloxacin Ophthalmic Solution USP, 0.5%, Sterile, 3mL Bottle, Rx Only, For Topical Ophthalmic Use Only, Distributed b	Drug	Class III	1
25 Nov 2019	Vancomycin Hydrochloride for Injection, USP, 1 g* per vial, packaged in 10-count vials per carton, Rx only, Mft. in Indi	Drug	Class II	1
20 Nov 2019	Mirtazapine Tablets, USP, 15 mg, 500-count tablets, Rx only, Distributed by: Aurobindo Pharma USA, Inc. Dayton, NJ 08810	Drug	Class I	2

All 23 events for AuroMedics Pharma LLC

Questions and answers

Why was this drug recalled?

FDA's record gives the reason for recall as: "Crystallization: Presence of visible particulate matter."

What does Class III mean?

FDA classifies recalls by relative degree of health hazard. Class III is a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.

Where was the product distributed?

FDA's distribution pattern field reads: "Distributed Nationwide in the US"

Is the recall still ongoing?

FDA lists the status as Terminated; the termination date is 1 Apr 2021. "Terminated" means FDA has determined that all reasonable efforts to remove or correct the product have been made.

Where does this data come from?

openFDA enforcement reports (food, drug and device), CC0, export dated 28 Sep 2026. Text in quotation marks is FDA's. The FDA enforcement report linked above is authoritative.

Provenance

Source: openFDA drug enforcement reports (CC0), export dated 28 Sep 2026; records grouped by FDA event number. The class shown for the event is the most severe class among its records. Errors in processing are corrected at the next build; see corrections.